Remicade 100 mg IV Injection (Janssen Biotech)

– The infusion should begin within 3 hours of reconstitution and dilution

– Infuse over at least 2 hours; do not infuse with other agents; use in-line low protein binding filter (≤1.2 micron)

– Temporarily discontinue or decrease infusion rate with infusion-related reactions.

– Antihistamines (H1-antagonist +/- H2-antagonist), acetaminophen and/or corticosteroids may be used to manage reactions. Infusion may be reinitiated at a lower rate upon resolution of mild to moderate symptoms.

– During infusion, if reaction is noted, monitor vital signs every 2 to 10 minutes, depending on reaction severity, until normal

– Active and latent TB screening prior to initiating and during therapy

– Signs/symptoms of infection (prior to, during, and following therapy)

– CBC with differential

– Signs/symptoms/worsening of heart failure

– HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy)

– Signs and symptoms of hypersensitivity reaction

– Symptoms of lupus-like syndrome

– LFTs (discontinue if >5 times ULN)

– Signs and symptoms of malignancy (splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).

– Psoriasis patients with history of phototherapy should be monitored for nonmelanoma skin cancer.